In yesterday’s Wall Street session, Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) shares traded at $11.68, down -2.59% from the previous session.
As of this writing, 5 analysts cover Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $28.00 and a low of $18.00, we find $20.00. Given the previous closing price of $11.99, this indicates a potential upside of 66.81 percent. KNSA stock price is now -15.81% away from the 50-day moving average and -7.44% away from the 200-day moving average. The market capitalization of the company currently stands at $832.43M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
There are 0 analysts who have given it a hold rating, whereas 5 have given it a buy rating. Brokers who have rated the stock have averaged $21.60 as their price target over the next twelve months.
With the price target enhanced from $25 to $40, BofA Securities maintained Buy rating for Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA). On April 01, 2020, BofA/Merrill recently initiated its ‘Buy’ rating on the stock quoting a target price of $25, while ‘Barclays’ rates the stock as ‘Overweight’.
In other news, Quart Barry D, Director sold 21,959 shares of the company’s stock on Nov 29. The stock was sold for $354,638 at an average price of $16.15. Upon completion of the transaction, the Director now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 07, CHIEF MEDICAL OFFICER Paolini John F. sold 28,357 shares of the business’s stock. A total of $430,459 was realized by selling the stock at an average price of $15.18. This leaves the insider owning 36,335 shares of the company worth $0.42 million. Insiders disposed of 70,637 shares of company stock worth roughly $0.83 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KNSA stock. A new stake in Kiniksa Pharmaceuticals Ltd. shares was purchased by SPHERA FUNDS MANAGEMENT LTD. during the first quarter worth $3,589,000. HILLSDALE INVESTMENT MANAGEMENT INC. invested $2,850,000 in shares of KNSA during the first quarter. In the first quarter, HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND acquired a new stake in Kiniksa Pharmaceuticals Ltd. valued at approximately $2,310,000. MARSHALL WACE, LLP acquired a new stake in KNSA for approximately $1,728,000. AQR CAPITAL MANAGEMENT LLC purchased a new stake in KNSA valued at around $1,694,000 in the second quarter. In total, there are 187 active investors with 45.50% ownership of the company’s stock.
Monday morning saw Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) opened at $12.06. During the past 12 months, Kiniksa Pharmaceuticals Ltd. has had a low of $7.36 and a high of $17.19. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.20, and a quick ratio of 4.70. The fifty day moving average price for KNSA is $13.87 and a two-hundred day moving average price translates $12.62 for the stock.
The latest earnings results from Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at $3.18, beating analysts’ expectations of $0.78 by 2.4. This compares to -$0.53 EPS in the same period last year. The net profit margin was 83.30% and return on equity was 66.70% for KNSA. The company reported revenue of $61.88 million for the quarter, compared to $18.75 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 230.14 percent. For the current quarter, analysts expect KNSA to generate $45.11M in revenue.
Kiniksa Pharmaceuticals Ltd.(KNSA) Company Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
